In collaboration with the pharmacy Sen’Su in Lausanne, we are organizing a conference focused on Genetics of food intolerances. It is taking place on 26^th of April, 2012 in Lausanne.

 

Dr. Goranka Tanackovic joined “Gene Predictis” at CEO position from September 2011.  Combining her strong entrepreneurial spirit and past experience, she is determined to further develop projects of “Gene Predictis” and contribute to its growth.

Dr. Tanackovic obtained M.Sc. degree in both Biology and Chemistry from the University of Osijek, Croatia. She then studied human hereditary disorders and, in 1999, earned Ph.D. in Biology from the University of Zagreb, Croatia. In 2000 she moved to Geneva, Switzerland, where she worked in the filed of RNA research and was awarded her second Ph.D. in Biology in 2004, from the University of Geneva. Her postdoctoral research was focused on molecular mechanisms involved in various genetic diseases. During her academic career, Dr. Tanackovic successfully led various research projects, obtained numerous research grants, and results of her work are recognized through the publications in high-impact per-reviewed journals.

In parallel with her Ph.D. studies, Dr. Tanackovic successfully completed entrepreneurship program of “Create” Switzerland (2002) and was one of the winners of “Venture Leaders” program in 2003. In this frame, she also successfully completed an entrepreneurship program at Babson College, Wellesley, USA (2003).

Dr. Annabel McQuillan joins Gene Predictis and will bring her experience and vision on how pharmacogenetics could help to improve psychiatric medicine.

Dr McQuillan was born in Edinburgh and studied medicine at the University of Glasgow. After internships in medicine and surgery she moved to Geneva to do her doctoral thesis in gastroenterology. Initially because of an interest in psychosomatic medicine she trained as a psychiatrist.

Her subsequent clinical interest in mood disorders, Borderline Personality Disorder (BPD) and suicidal behavior led to a specialized training with Professor M. Linehan in Seattle. On her return she developed the CARE Program, an out-patient treatment facility within the Department of Psychiatry. This program delivers innovative evidenced based treatment combing a modern psychotherapeutic approach with pharmacological treatments for patients suffering from BPD and ongoing suicidal and self-harming behaviors. Dr McQuillan has taught for many years on both clinical and theoretical aspects of these pathologies, as well as authoring scientific papers and conferences.

Over the years Dr McQuillan has participated actively in implementing novel treatment strategies in an attempt to improve clinical outcomes and particularly to reduce hospitalization rates. She is currently working in psychopharmacology.